Evidence map›Paper›PMID 24376649›Full record

ArticlePloS one2013

Trends in detection of invasive cancer and ductal carcinoma in situ at biennial screening mammography in Spain: a retrospective cohort study.

Marta Román, Montse Rué, Maria Sala, Nieves Ascunce, Marisa Baré, Araceli Baroja, Mariola De la Vega, Jaume Galcerán, Carmen Natal, Dolores Salas and 4 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Observational
  2. The need for a rapid and comprehensive adoption of the revised European standard population in cancer incidence comparisons.European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP) · 2017
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 8 institutions in 1 country.

Marta RománDepartment of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain ; Network for Research into Healthcare in Chronic Diseases (REDISECC), Madrid, Spain.
Montse RuéNetwork for Research into Healthcare in Chronic Diseases (REDISECC), Madrid, Spain ; Basic Medical Sciences Department, Biomedical Research Institut of Lleida (IRBLLEIDA)-University of Lleida, Lleida, Spain.
Maria SalaDepartment of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain ; Network for Research into Healthcare in Chronic Diseases (REDISECC), Madrid, Spain ; Universitat Autònoma de Barcelona, Barcelona, Spain.
Nieves AscunceNavarra Breast Cancer Screening Programme, Public Health Institute, Pamplona, Navarra, Spain.
Marisa BaréOficina Tècnica de Cribratge, Corporació Sanitaria Parc Taulí-Institut Universitari Parc Taulí-UAB, Sabadell, Barcelona, Spain.
Araceli BarojaLa Rioja Breast Cancer Screening Programme, Fundacion Rioja Salud, Logroño, La Rioja, Spain.
Mariola De la VegaDirección General de Programas Asistenciales, Consejería de Sanidad, Servicio Canario de Salud, Tenerife, Santa Cruz de Tenerife, Spain.
Jaume GalceránFoundation Society for Cancer Research and Prevention, Pere Virgili Health Research Institute, Reus, Tarragona, Spain.
Carmen NatalProgram & Analysis Unit, Health Office, Oviedo, Principado de Asturias, Spain.
Dolores SalasGeneral Directorate Public Health & Centre for Public Health Research, Valencia, Comunidad Valenciana, Spain.
Mercedes Sánchez-JacobServicio de Promoción de la Salud y Programas Preventivos, Consejería de Sanidad, Valladolid, Castilla y León, Spain.
Raquel ZubizarretaGalician Breast Cancer Screening Programme, Public Health & Planning Directorate, Health Office, Santiago de Compostela, La Coruña, Spain.
Xavier CastellsDepartment of Epidemiology and Evaluation, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain ; Network for Research into Healthcare in Chronic Diseases (REDISECC), Madrid, Spain ; Universitat Autònoma de Barcelona, Barcelona, Spain.
Cumulative False Positive Risk Group
Municipal Institute for Medical Research · ESBiomedical Research Institute of Lleida · ESCorporació Sanitària Parc Taulí · ESGeneralitat Valenciana · ESGobierno del Principado de Asturias · ESInstitut d'Investigació Sanitària Pere Virgili · ESServicio Canario de la Salud · ESUniversitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer incidence has decreased in the last decade, while the incidence of ductal carcinoma in situ (DCIS) has increased substantially in the western world. The phenomenon has been attributed to the widespread adaption of screening mammography. The aim of the study was to evaluate the temporal trends in the rates of screen detected invasive cancers and DCIS, and to compare the observed trends with respect to hormone replacement therapy (HRT) use along the same study period.

methodsRetrospective cohort study of 1,564,080 women aged 45-69 years who underwent 4,705,681 screening mammograms from 1992 to 2006. Age-adjusted rates of screen detected invasive cancer, DCIS, and HRT use were calculated for first and subsequent screenings. Poisson regression was used to evaluate the existence of a change-point in trend, and to estimate the adjusted trends in screen detected invasive breast cancer and DCIS over the study period.

resultsThe rates of screen detected invasive cancer per 100.000 screened women were 394.0 at first screening, and 229.9 at subsequent screen. The rates of screen detected DCIS per 100.000 screened women were 66.8 at first screen and 43.9 at subsequent screens. No evidence of a change point in trend in the rates of DCIS and invasive cancers over the study period were found. Screen detected DCIS increased at a steady 2.5% per year (95% CI: 1.3; 3.8), while invasive cancers were stable.

conclusionDespite the observed decrease in breast cancer incidence in the population, the rates of screen detected invasive cancer remained stable during the study period. The proportion of DCIS among screen detected breast malignancies increased from 13% to 17% throughout the study period. The rates of screen detected invasive cancer and DCIS were independent of the decreasing trend in HRT use observed among screened women after 2002.

Indexed as

AgedBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingEarly Detection of CancerFemaleHormone Replacement TherapyHumansIncidenceMammographyMass ScreeningMiddle AgedRetrospective StudiesSpain

Identifiers

PMID24376649
PMCPMC3871523
OpenAlexW2094297303

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.